Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.

Dr. Peter Hendricks is an Associate Professor in the University of Alabama at Birmingham’s (“UAB”) Health and Behavior department where he has led studies and authored a number of published research articles that explore the therapeutic impacts of psychedelic drugs, including psilocybin. UAB is one of the few universities in the world currently investigating the medicinal benefits of psilocybin.

“Peter’s background in drug and behavioral research strongly supplements our team as we pursue and assess new opportunities,” said Eric Weisblum, CEO of Silo Pharma, Inc. “Our Scientific Advisory Board is comprised of some of the most forward-thinking researchers in the industry, and will help to position Silo Pharma, Inc. as a critical player in the pursuit of ground-breaking research and innovation in the field of psychedelic medicine.”

Dr. Hendricks has served as Associate Professor at UAB since 2010. He has focused his research on the interplay between psychedelic-assisted psychotherapy and a host of sociological issues such as criminality, substance abuse, and suicide. His most current area of research focused on the evaluation of the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics.

“Silo Pharma, Inc. will continue to support the research of commercially viable tools and drugs that seek superior outcomes for individuals suffering from emotional and behavioral disorders,” added Weisblum. “The use of psychedelic drugs such as psilocybin, as an alternative therapy, have the potential to be a disruptive force in the treatment of these widespread conditions. I look forward to working with Dr. Hendricks in pursuit of opportunities in this field.”  

Dr. Hendricks earned his Doctor of Philosophy from the University of South Florida in 2006.

About Silo Pharma

Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:                                      

Hayden IR

Brett Maas
646-536-7331
Email: brett@haydenir.com